[go: up one dir, main page]

FI20011671L - Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö - Google Patents

Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö Download PDF

Info

Publication number
FI20011671L
FI20011671L FI20011671A FI20011671A FI20011671L FI 20011671 L FI20011671 L FI 20011671L FI 20011671 A FI20011671 A FI 20011671A FI 20011671 A FI20011671 A FI 20011671A FI 20011671 L FI20011671 L FI 20011671L
Authority
FI
Finland
Prior art keywords
tumor
oligosaccharide sequences
specific oligosaccharide
specific
sequences
Prior art date
Application number
FI20011671A
Other languages
English (en)
Swedish (sv)
Other versions
FI20011671A0 (fi
Inventor
Jari Natunen
Susann Teneberg
Karl-Anders Karlsson
Original Assignee
Carbion Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carbion Oy filed Critical Carbion Oy
Priority to FI20011671A priority Critical patent/FI20011671L/fi
Publication of FI20011671A0 publication Critical patent/FI20011671A0/fi
Priority to JP2003521371A priority patent/JP2005500535A/ja
Priority to EP02753102.9A priority patent/EP1419393B1/en
Priority to US10/487,203 priority patent/US8236487B2/en
Priority to PCT/FI2002/000681 priority patent/WO2003016915A1/en
Publication of FI20011671L publication Critical patent/FI20011671L/fi
Priority to DK03792440.4T priority patent/DK1534324T3/en
Priority to US10/525,011 priority patent/US8697061B2/en
Priority to US14/223,346 priority patent/US20140234318A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
FI20011671A 2001-08-20 2001-08-20 Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö FI20011671L (fi)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FI20011671A FI20011671L (fi) 2001-08-20 2001-08-20 Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
JP2003521371A JP2005500535A (ja) 2001-08-20 2002-08-20 腫瘍特異的オリゴ糖配列およびその用途
EP02753102.9A EP1419393B1 (en) 2001-08-20 2002-08-20 Tumor specific oligosaccharide sequences and use thereof
US10/487,203 US8236487B2 (en) 2001-08-20 2002-08-20 Tumor specific oligosaccharide sequences and use thereof
PCT/FI2002/000681 WO2003016915A1 (en) 2001-08-20 2002-08-20 Tumor specific oligosaccharide sequences and use thereof
DK03792440.4T DK1534324T3 (en) 2001-08-20 2003-08-20 TUMOR SPECIFIC OLIGOSACCHARIDE EPITOPES AND USE THEREOF
US10/525,011 US8697061B2 (en) 2001-08-20 2003-08-20 Tumor specific oligosaccharide epitopes and use thereof
US14/223,346 US20140234318A1 (en) 2001-08-20 2014-03-24 Tumor specific oligosaccharide epitopes and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20011671A FI20011671L (fi) 2001-08-20 2001-08-20 Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö

Publications (2)

Publication Number Publication Date
FI20011671A0 FI20011671A0 (fi) 2001-08-20
FI20011671L true FI20011671L (fi) 2003-02-21

Family

ID=8561761

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20011671A FI20011671L (fi) 2001-08-20 2001-08-20 Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö

Country Status (6)

Country Link
US (3) US8236487B2 (fi)
EP (1) EP1419393B1 (fi)
JP (1) JP2005500535A (fi)
DK (1) DK1534324T3 (fi)
FI (1) FI20011671L (fi)
WO (1) WO2003016915A1 (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011671L (fi) 2001-08-20 2003-02-21 Carbion Oy Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
US20050026866A1 (en) * 2002-08-02 2005-02-03 Pawelek John M. Agents and methods for treatment of disease by oligosaccharide targeting agents
EP1534324B1 (en) * 2002-08-20 2019-01-16 Glykos Finland Oy Tumor specific oligosaccharide epitopes and use thereof
FI20055398A0 (fi) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
CA2652232A1 (en) 2005-07-11 2007-01-18 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
EP1913385B1 (en) * 2005-07-11 2013-08-21 Glykos Finland Oy Tissue carbohydrate compositions and analysis thereof
FI20055417A0 (fi) * 2005-07-20 2005-07-20 Glykos Finland Oy Syöpäpesifiset glykaanit ja niiden käyttö
EP3438131B1 (en) 2006-02-10 2022-03-16 Life Technologies Corporation Oligosaccharide modification and labeling of proteins
FI20075030A0 (fi) 2007-01-18 2007-01-18 Suomen Punainen Risti Veripalv Menetelmä solujen modifioimiseksi
CA2712556A1 (en) 2007-01-18 2008-07-24 Glykos Finland Ltd Novel carbohydrate from human cells and methods for analysis and modification thereof
CA2712562A1 (en) 2007-01-18 2008-07-24 Glykos Finland Ltd Novel specific cell binders
JP2010516239A (ja) 2007-01-18 2010-05-20 スオメン プナイネン リスティ，ヴェリパルベル 細胞の産生に対する新規方法および試薬
US20080318332A1 (en) * 2007-05-29 2008-12-25 Mechref Yehia S Disease diagnosis by profiling serum glycans
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
US10174360B2 (en) 2012-04-10 2019-01-08 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Methods for analyzing glycan-derived monosaccharides
FI3912642T3 (fi) 2012-10-23 2023-07-07 Synaffix Bv Muokattu vasta-aine, vasta-ainekonjugaatti ja menetelmä niiden valmistamiseksi
WO2015120362A1 (en) * 2014-02-10 2015-08-13 Albert Einstein College Of Medicine Of Yeshiva University Methods of grading carcinomas
JP2017528124A (ja) 2014-08-04 2017-09-28 シンアフィックス ビー．ブイ． ベータ−（１，４）−ｎ−アセチルガラクトサミニルトランスフェラーゼ又はその突然変異体を用いる糖タンパク質の改変方法
EP3134520B1 (en) 2015-04-23 2017-12-20 Synaffix B.V. Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a (1,4)-n-acetylgalactosaminyltransferase
US10758612B2 (en) * 2015-07-15 2020-09-01 Washington University Antibodies to tumor associated complex N-glycans with terminal GlcNAcβ residues and methods of use thereof
EP3806866B1 (en) * 2018-06-14 2022-11-16 Mayo Foundation for Medical Education and Research Methods and materials for treating glycosylation disorders
US11506664B1 (en) * 2021-04-23 2022-11-22 Academia Sinica Methods for detecting and treating cholangiocarcinoma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618443D0 (en) * 1986-07-29 1986-09-03 Univ London Monoclonal antibodies
JP2579497B2 (ja) 1987-09-07 1997-02-05 オリエンタル酵母工業株式会社 肝臓疾患診断剤
GB8726271D0 (en) * 1987-11-10 1987-12-16 Univ London Protein glycosylation assay
DE3807594A1 (de) * 1988-03-08 1989-09-21 Reutter Werner Antikoerper, verfahren zu ihrer herstellung, oligosaccharid-haptene und klone zur erzeugung der antikoerper sowie verwendung der antikoerper zur diagnose und therapie von tumoren
CA1313496C (en) * 1988-04-29 1993-02-09 James Wilson Dennis Diagnostic method to screen tumors
JPH02264864A (ja) * 1989-04-04 1990-10-29 Shin Etsu Chem Co Ltd Ｇｓａ―２結合性蛋白質の免疫学的測定試薬及びそれを用いた免疫学測定用キット
DE4009630C2 (de) 1990-03-26 1995-09-28 Reinhard Prof Dr Dr Brossmer CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung
US6075134A (en) * 1997-05-15 2000-06-13 The Regents Of The University Of California Glycoconjugates and methods
AU1443900A (en) * 1998-10-09 2000-05-01 University Technology Corporation Glycoprotein antigens, antibodies specific thereto and method for producing same
JP4351314B2 (ja) * 1998-12-24 2009-10-28 大塚製薬株式会社 コレスタノール化合物及びこれを含有する医薬
GB0012216D0 (en) 2000-05-19 2000-07-12 European Molecular Biology Lab Embl Glycosyltransferase protein
FI20010118L (fi) * 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
FI20011664L (fi) * 2001-08-17 2003-02-18 Carbion Oy Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
FI20011671L (fi) 2001-08-20 2003-02-21 Carbion Oy Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2006068758A2 (en) 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention and treatment of breast cancer
US20070265170A1 (en) * 2006-05-15 2007-11-15 Ola Blixt Detection, prevention and treatment of ovarian cancer

Also Published As

Publication number Publication date
EP1419393A1 (en) 2004-05-19
US8236487B2 (en) 2012-08-07
DK1534324T3 (en) 2019-04-08
WO2003016915A8 (en) 2004-02-05
FI20011671A0 (fi) 2001-08-20
US20050014718A1 (en) 2005-01-20
US20140234318A1 (en) 2014-08-21
US20060014672A1 (en) 2006-01-19
JP2005500535A (ja) 2005-01-06
WO2003016915A1 (en) 2003-02-27
EP1419393B1 (en) 2014-08-13
US8697061B2 (en) 2014-04-15

Similar Documents

Publication Publication Date Title
FI20011671L (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DE60208385D1 (de) Antineoplasische kombinationspräparate
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
FI20011664L (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
ID30590A (id) Celana sekali pakai jenis-celana pendek
DE50208638D1 (de) Katheter
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
ATE299873T1 (de) Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate
FI20012016L (fi) Eettereitä hajottavia bakteereita ja niiden käyttö
FR2827943B3 (fr) Profile en c
DE60219418D1 (de) Silanylphenole und -naphthole
NO20030946L (no) Medisinske sammensetninger
EE200300563A (et) Bensüülaminopürimidiiniühendid, nende kasutamine ja ravim
SE0100590D0 (sv) New composition and use
DE60206034D1 (de) Spritze
DE60204435D1 (de) Spritze
DK1427748T3 (da) 17alfa-hydroxy-14beta-steroider med hormonal virkning
SE0104404D0 (sv) New methods and use
ITMI20011210A0 (it) Corticosteroidi-21-glicolati e 21-acilglicolati
SE0004405D0 (sv) New composition and use
ITGE20010029V0 (it) Passaverdura motorizzato
FI20011835A0 (fi) Flavonoidikoostumus ja sen valmistus ja käyttö
FI20011600A0 (fi) Generinen protokollarakenne ja rakenteen käyttö

Legal Events

Date Code Title Description
MA Patent expired